NKTX vs NTLA
NKTX: Nkarta is a clinical-stage biotechnology company pioneering off-the-shelf, engineered natural killer (NK) cell therapies to treat autoimmune diseases by depleting pathogenic B cells. NTLA: Intellia Therapeutics is a genome editing pioneer developing CRISPR/Cas9-based, potentially curative in vivo therapies for genetic diseases.
Side-by-side fundamentals
| Metric | NKTX | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.22 | $12.60 | |
| Market cap | $159M | $1.8B | |
| Net margin FY2025, SEC XBRL | n/a | -609.9% | |
| Operating margin FY2025, SEC XBRL | n/a | -651.7% | |
| ROE FY2025, SEC XBRL | -33.3% | -61.5% | NKTX higher |
| ROA FY2025, SEC XBRL | -25.8% | -49.0% | NKTX higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +12.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.25 | 1.66 | |
| 1-year return as of 2026-10-08 close | +6.2% | -48.5% | NKTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.